Enhertu

Targeted cancer treatment composed of a monoclonal antibody (fam-trastuzumab) and a chemotherapy drug (topoisomerase I inhibitor). This HER2-directed antibody and topoisomerase inhibitor conjugate is designed to specifically target and treat HER2-positive cancers, offering a more focused approach compared to traditional chemotherapy. Enhertu is primarily intended for patients with HER2-positive cancers, including breast and gastric cancers, who may benefit from targeted therapy.